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Pffects of Fluvastatin on the Carotid Arterial
edia as Assessed by Integrated Backscatter
ltrasound Compared With Pulse-Wave Velocity
aruko Yokoyama, MD, Masanori Kawasaki, MD, PHD, Yoko Ito, MD, PHD,
hinya Minatoguchi, MD, PHD, Hisayoshi Fujiwara, MD, PHD
ifu, Japan
OBJECTIVES Our goal is to show the effectiveness of fluvastatin in reducing arterial sclerosis using integrated
backscatter (IB) values rather than depending on the pulse-wave velocity (PWV) and stiffness
beta.
BACKGROUND Atherosclerotic changes consist of two components: atherosis as a structural change and
sclerosis as a functional change; IB ultrasound of carotid media was useful for assessment of
arterial sclerosis.
METHODS We measured IB values in the media of 40 segments of carotid arteries in 40 patients with
hyperlipidemia before and after statin therapy or diet for 12 months (fluvastatin [F group] 40
mg/day, n  20; control [C group]: diet, n  20). Pulse-wave velocity, intima-media
thickness, and stiffness beta were measured at the same time.
RESULTS At baseline, IB values correlated with PWV (r 0.71, p 0.001) and stiffness beta (r 0.47,
p  0.002) in 40 patients with hyperlipidemia. Integrated backscatter values did not change
in the C group but decreased in the F group (from 12.3  2.1 dB to 11.3  2.1 dB, p 
0.002). Also, PWV increased in the C group (from 1,728  687 cm/s to 1,771  716 cm/s,
p  0.021) but decreased in the F group (from 1,848  582 cm/s to 1,768  549 cm/s,
p  0.012). Stiffness beta decreased in the F group (from 14.0  3.9 to 12.1  3.5, p 
0.002).
CONCLUSIONS Statin therapy with fluvastatin improved arterial sclerosis as assessed by IB values. (J Am
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.06.084Coll Cardiol 2005;46:2031–7) © 2005 by the American College of Cardiology Foundation
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ptherosclerotic changes consist of two components: athero-
is as a structural change and sclerosis as a functional
hange. According to a pathological study, atherotic
hanges are recognized by an increase in the intima-media
hickness (IMT), which is associated with structural ather-
matous changes, and sclerotic changes are recognized by a
ecreased extensibility, which is associated with functional
clerotic changes in elastic and collagen fibers. Intima-
edia thickness measurement is widely used to evaluate
theromatous damages, which are associated with age and
oronary risk factors (1). However, increased thickness of
he wall as determined by IMT measurement is not always
ssociated with the severity of “sclerosis” in patients with
ypertension (HTN) (2). This lack of association may be
ue to the degenerative changes in the medial smooth
uscle cells and variation in the increased amount of elastin
nd collagen in hypertensive vessels. Arterial stiffness is
ainly correlated with the amounts of medial elastin and
ollagen, rather than the thickness of the arterial wall (3).
n the other hand, there is another ultrasound parameter,
tiffness beta, which is used to evaluate sclerosis and is
ssociated with decreased extensibility of the arterial wall.
tiffness beta was found to be independent of blood pressure
ithin the normal physiological range and was associated
ith the severity of coronary atherosclerosis (4,5).
From Regeneration & Advanced Medical Science, Gifu University Graduate
chool of Medicine, Gifu, Japan.t
Manuscript received February 24, 2005; revised manuscript received June 1, 2005,
ccepted June 6, 2005.With respect to atherosis of arterial plaques, we reported
n the tissue characterization of arterial plaques in human
arotid arteries (6). These studies showed that ultrasound
ntegrated backscatter (IB) values accurately reflected the
issue characteristics of human carotid arterial plaques.
ther investigators showed that measurements of IB values
f the carotid arteries are clinically useful for risk assessment
f coronary artery disease (CAD) patients (7). With respect
o sclerosis, we reported that the measurement of the IB
alue of the carotid media is useful in evaluating arterial
clerosis in vivo as well as the stiffness beta and that IB
alues are associated with the structural change of the elastic
ber and collagen fiber of carotid media (8).
When considering therapies, we know that 3-hydroxy-3-
ethylglutaryl coenzyme A reductase inhibitor drugs (statins)
educe mortality of myocardial infarction and stroke, pre-
enting the progression of atherosis as assessed by IMT
9,10). A previous study has shown an association between
he IMT of carotid arteries and incidence of myocardial
nfarction and stroke (11). We previously reported that
ydrophilic statin treatment did not improve arterial scle-
osis as assessed by IB values (12). Hydrophilic statin cannot
ross the cell membranes of the vascular wall. However,
uvastatin can and it has a strong anti-proliferative effect on
mooth muscle cells because it is lipophilic (13). In the
resent study, we measured IB values in the carotid media in
atients with hyperlipidemia (HL) before and after statin
herapy to define whether fluvastatin reduces arterial scle-
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Effects of Fluvastatin on the Carotid Media December 6, 2005:2031–7osis. Our goal is to show the effectiveness of fluvastatin in
educing arterial sclerosis using IB values.
ETHODS
ubjects. This study was a simple randomization, open-
abel, single-center study of patients with HL. Patients were
ither previously untreated or treated with drugs other than
tatins, but with total cholesterol concentrations remaining
bove 220 mg/dl. Patients with unstable angina or myocar-
ial infarction within the previous three months, an ejection
raction 30%, and secondary causes of hypercholesterol-
mia were excluded from the present study. They were
andomized to a statin treatment group of fluvastatin (F group:
0 mg/day, n  20) or a control group (C group: n  20).
tudy patients in the control group were referred to a nu-
ritionist for individual counseling and were also provided with
lifestyle-changing program that included diet and smok-
ng cessation. The protocol was approved by the institu-
ional ethics committee, and informed consent was obtained
rom all patients before enrollment.
tudy protocol. We measured IB values of one site in the
ar wall of the media of right common carotid arteries of
ach patient; IB values were evaluated at baseline and after
2 months in the patients with statin therapy and in patients
ith diet. At the same time, we also measured IMT and
igure 1. Integrated backscatter (IB) image from the carotid artery. (A) Co
nd diameter of artery were measured on conventional ultrasound image. B
Abbreviations and Acronyms
ApoB/A-I  ratio of apolipoprotein B to
apolipoprotein A-I
CAD  coronary artery disease
CVD  cerebrovascular disease
DM  diabetes mellitus
HL  hyperlipidemia
hs-CRP  high-sensitivity C-reactive protein
HTN  hypertension
IB  integrated backscatter
IMT  intima-media thickness
LDL-C  low-density lipoprotein cholesterol
PWV  pulse-wave velocity
SBP  systolic blood pressurerteries (an angle span of 30° between 15° and 15°) were measured. The IB
oving the region of interest above the far arterial site. Also, IB values of arterial ltiffness beta by conventional ultrasound in the same seg-
ent of the carotid arteries in which IB was measured.
urthermore, fasting plasma concentrations of total choles-
erol, low-density lipoprotein cholesterol (LDL-C), high-
ensity lipoprotein cholesterol, triglycerides, hemoglobin
1c (HbA1c), high-sensitivity C-reactive protein (hs-
RP), and body mass index were analyzed. Brachial-ankle
ulse-wave velocity (PWV) was also measured on the same
ay as ultrasound analysis and blood examination. The same
easurements were also performed in the C group. We also
valuated the incidence of other atherosclerotic risk factors
n each patient including HTN, diabetes mellitus (DM),
moking status, history of cerebrovascular disease (CVD),
nd CAD.
B system presets and data acquisition. Transverse and
ongitudinal scans were performed between the middle of
he right common carotid arteries and bifurcation of the
xternal carotid artery and the internal carotid artery using
n ultrasound imaging system (SONOS 5500, Philips
edical Systems, Andover, Massachusetts). We performed
B measurements using cross-sectional images rather than
ongitudinal images because the same method had been
sed in our previous study. Cross-sectional IB images were
cquired at a site of 10 mm away from the bifurcation. We
sed the distance between the site of measurement and the
ifurcation to locate the corresponding sites after 12 months.
onventional echocardiography and IB images were easily
cquired at the bedside using a 5- to 12-MHz transducer for all
tudies (Figs. 1A and 1B). The details of our measurements
ave been previously reported (8,12); IB values in the far wall
f the arteries (an angle span of 30° between 15° and 15°)
ere measured (Fig. 1C). The IB values were determined by
veraging the IB values from 10 sites continuously moving the
egion of interest above the far arterial site. The IB values of
he far wall were corrected by subtracting the minimum IB
alues of the vessel lumen just above the far wall. The
ntraobserver variability of IB values was 6.5% to 7.2% (r 
.89, p  0.01), and the interobserver variability of IB values
as 7.4% to 9.4% (r  0.87, p 0.01) (8).
ional ultrasound image of common carotid artery. Intima-media thickness
1 cm. (B and C) Integrated backscatter values in the entire far wall of thenvent
ar values were determined averaging the IB values from 10 sites continuously
umen were measured just above far wall shown by an asterisk. Bar  1 cm.
N
w
A
s
a
m
v
s
0
(
c
a
a
v
S
m
t
t
a
s
L
b
g
T
p
C
P
l
s
R
C
p
e
4
2
c
d
i
t
F
a
i
T
C
M
A
B
C
M
V
2033JACC Vol. 46, No. 11, 2005 Yokoyama et al.
December 6, 2005:2031–7 Effects of Fluvastatin on the Carotid Mediaon-invasive vascular parameters. Brachial-ankle PWV
as measured using a pulse pressure analyzer (Form PWV/
BI, Colin Medical Technology, Komaki, Japan), which
imultaneously record blood pressure, electrocardiogram,
nd heart sound after at least 5 min rest. Details of the
easurements were described in a previous report (14). The
alidation of this method has been reported: the intraob-
erver coefficient of variation was 10.0% (r  0.87, p 
.01) and the interobserver coefficient of variation was 8.4%
r  0.98, p  0.01) (14). In addition, the stiffness beta was
igure 2. Correlation among integrated backscatter (IB) values, ultrasound
able 1. Summary of Demographics and Baseline
haracteristics of the Patients
Variables
Fluvastatin
(n  20)
Control
(n  20) p Value
en 7 (35) 8 (40) 0.74
ge, yrs 61  10 61  11 0.44
ody mass index, kg/m2 24.1  2.5 23.4  2.7 0.52
linical history
Ischemic heart disease 4 (20) 5 (25) 0.71
Hypertension 8 (40) 6 (30) 0.51
Diabetes mellitus type 2 3 (15) 3 (15) 1.00
Current smoker 4 (20) 5 (25) 0.71
edication
Aspirin 2 (10) 3 (15) 0.63
Ticlopidine 3 (15) 2 (10) 0.63
Nitrates 3 (15) 3 (15) 1.00
Nicorandil 3 (15) 4 (20) 0.68
Diuretic 2 (10) 2 (10) 1.00
Calcium-channel blockers 7 (35) 3 (15) 0.14
Beta-blockers 0 (0) 1 (5) 0.31
ACE inhibitors 1 (5) 1 (5) 1.00
Insulin 1 (5) 1 (5) 1.00
alues are mean  SD or n (%).
ACE  angiotensin-converting enzyme.t baseline. (A) Correlation between IB values and PWV. (B) Correlation betw
ntima-media thickness. (D) Correlation between IB values and age.alculated from the measurement of blood pressure and
rterial diameter. The arterial diameter of the carotid
rteries was measured in the same segment in which IB
alues were measured.
tatistical analysis. Numerical data were expressed as
ean values  SD. The Kolmogrov-Smirnov test showed
hat all data were normally distributed. The significance of
he differences between various parameters at baseline and
fter 12 months was tested using a paired t test. The
ignificance of the differences in total cholesterol and
DL-C between the groups was tested using Welch’s t test,
ecause the variances of these parameters between the
roups were significantly different as tested by the F-test.
he significance of the differences between groups in other
arameters was tested by an unpaired Student t test.
orrelations among IB values, ultrasound parameters, and
WV of the patients with HL at baseline were tested by
inear regression analysis. A p value 0.05 was considered
ignificant.
ESULTS
linical characteristics and parameters at baseline. No
atient experienced significant (3  upper limit of normal)
levations of liver-associated enzymes or had myositis. All of
0 patients (age 28 to 82 years, 61  10 years, 15 men and
5 women) completed the study. There were no serious
ardiovascular and cerebrovascular events including myocar-
ial infarction, unstable angina, cerebral infarction, or death
n both study groups. Table 1 presents the baseline charac-
eristics of the study population. Baseline characteristics
eters, and pulse-wave velocity (PWV) of the patients with hyperlipidemiaparam
een IB values and stiffness beta. (C) Correlation between IB values and
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Effects of Fluvastatin on the Carotid Media December 6, 2005:2031–7etween the patients in the F group and the C group were
ot significantly different.
Pulse-wave velocity at baseline strongly correlated with
B values at baseline (r  0.71, p  0.0001). Stiffness beta,
MT, and age correlated with IB values (r 0.47, 0.55, and
.61, respectively) (Fig. 2). The ratio of apolipoprotein B to
polipoprotein A-I (ApoB/A-I), HbA1c, and systolic blood
ressure (SBP) at baseline weakly correlated with IB values
t baseline (r 0.37, 0.46, and 0.46, respectively, p 0.01).
ntegrated backscatter values in the patients with DM were
ignificantly greater than those in the patients without DM;
B values in the patients with HTN were significantly
reater than those in the patients without HTN. However,
moking and history of CVD and CAD did not correlate
ith IB values (Fig. 3).
hange of clinical parameters after statin therapy. Lipid
alues of patients in each group, at baseline and at 12
onths, are shown in Table 2. At baseline, clinical param-
ters did not differ between groups. After initiating statin
herapy, the lipid profile significantly improved, but re-
ained unchanged in the control group.
Baseline IB values and other characteristics and parame-
ers were similar between the study groups. Table 3 shows
he non-invasively determined ultrasound parameters, blood
ressure, and PWV. At baseline, no significant differences
ere found in these parameters between the F group and the
group. The IB values, PWV, and stiffness beta signifi-
igure 3. Comparison of integrated backscatter (IB) values between the
atients with atherosclerotic risk factors and without risk factors. Values
epresent mean  one SD. CAD history of coronary artery disease; CVD
history of cerebrovascular disease; DM  diabetes mellitus; HTN 
ypertension.antly decreased in the F group after 12 months. However,
*B values and stiffness beta did not change significantly in
he C group but decreased in the F group (from 0.90 0.26
m to 0.86  0.27 mm, p  0.012). However, IMT
ignificantly increased in the C group (from 0.87  0.25
m to 0.92  0.27 mm, p  0.018). There was no
ignificant change in SBP and diastolic blood pressure.
owever, SBP showed a slight decrease in the F group
from 141  23 mm Hg to 136  19 mm Hg, p  0.051).
able 2. Changes in Lipid Parameters
Parameters Baseline Month 12 Change (%)
otal-C (mg/dl)
Fluvastatin 247  58 202  35*‡ 18.2
Control 250  22 243  20† 2.8
DL-C (mg/dl)
Fluvastatin 52  17 57  14 9.6
Control 57  18 55  16 3.5
DL-C (mg/dl)
Fluvastatin 154  46 118  29*‡ 23.4
Control 156  18 156  18 0
riglycerides (mg/dl)
Fluvastatin 189  74 154  88† 18.5
Control 176  65 167  56 0.5
bA1c (mg/dl)
Fluvastatin 6.1  1.7 5.9  1.2 3.2
Control 5.7  1.2 5.7  1.0 0
s-CRP (ng/ml)
Fluvastatin 2,094  2,712 1,775  2,347 15.2
Control 2,011  1,937 2,142  1,839 6.5
poB/A-I
Fluvastatin 0.90  0.24 0.72  0.19*‡ 20.0
Control 0.91  0.20 0.93  0.23 2.2
p  0.01, †p  0.05, difference between baseline and after 12 months; ‡p  0.01,
ifference among fluvastatin and control.
ApoB/A-I  ratio of apolipoprotein B to apolipoprotein A-I; HbA1c 
emoglobin A1c; HDL-C  high-density lipoprotein cholesterol; hs-CRP 
igh-sensitivity C-reactive protein; LDL-C  low-density lipoprotein cholesterol.
able 3. Changes in Ultrasound and Hemodynamic Parameters
Parameters Baseline Month 12
Change
(%)
B value (dB)
Fluvastatin 12.3  2.1 11.3  2.1* 7.3
Control 12.1  2.7 12.4  2.2 2.4
ulse-wave velocity
(cm/s)
Fluvastatin 1,848  582 1,768  549† 4.3
Control 1,728  687 1,771  716† 2.4
MT (mm)
Fluvastatin 0.90  0.26 0.86  0.27† 4.4
Control 0.87  0.25 0.92  0.27† 5.7
tiffness parameter beta
Fluvastatin 14.0  3.9 12.1  3.5* 13.6
Control 12.7  3.5 13.0  4.2 2.4
ystolic blood pressure
(mm Hg)
Fluvastatin 141  23 136  19 3.5
Control 129  21 133  18 3.1
iastolic blood pressure
(mm Hg)
Fluvastatin 81  15 78  15 3.7
Control 80  12 81  14 1.2p  0.01, †p  0.05, difference between baseline and after 12 months.
IB  integrated backscatter; IMT  intima-media thickness.
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December 6, 2005:2031–7 Effects of Fluvastatin on the Carotid Mediahe change of IB values between baseline and after 12
onths (IB values) significantly correlated with the
hange between baseline and 12 months () of ApoB/A-I
ApoB/A-I), LDL-C, triglycerides, and ApoB (r 
.56, 0.47, 0.33, and 0.38, respectively). The change of
WV between at baseline and after 12 months (PWV)
orrelated with only ApoB/A-I and triglycerides (r 
.36 and 0.49, respectively) (Fig. 4); IMT tended to
orrelate with ApoB/A-I (r  0.28, p  0.077) and
ApoB (r  0.27, p  0.087).
ISCUSSION
B values as a parameter for the assessment of arterial
clerosis. The elasticity of major arteries is affected by
ardiovascular risk factors such as HTN, HL, DM, and
ging. An increase in arterial stiffness has been reported as
n early sign of atherosclerosis (4). On the other hand, one
tudy found that there was increased carotid stiffness related
o IMT only in patients whose IMT was in the highest
uartile of IMT (15). Another study found no association
etween IMT and increased arterial stiffness except for
atients with arterial walls rated in the top 10% for thickness
16). Our previous study found no relation between arterial
clerosis (as measured by stiffness beta and IB values of
arotid media) and atherosis (as measured by IMT) in
igure 4. Correlation of the change () of integrated backscatter (IB) val
ith lipid change between baseline and after 12 months. ApoB/A-I  the
nd after 12 months; LDL-C  low-density lipoprotein cholesterol; TGatients with systemic sclerosis (8). Therefore, sclerosis and otherosis should not be considered as the same physiological
hange.
Pulse-wave velocity represents a useful integrated index of
ascular stiffness and hence cardiovascular risk (17). Inte-
rated backscatter values at baseline significantly correlated
ith PWV and stiffness beta (Fig. 2). This fact suggests that
igh IB values of carotid media may indicate stiffness of the
arotid arteries, although PWV is differentiated from IB
alues because PWV is affected by peripheral arteries,
hereas the IB value of carotid media is affected only by
arotid arteries.
ffects of statin therapy on arterial media. There are two
ypes of statins: lipophilic, for example, fluvastatin, and
ydrophilic, pravastatin. Fluvastatin, because it is lipophilic,
an cross the cell membranes of nearly all tissues including
he vascular wall. Several large-scale clinical trials using
onventional ultrasound have demonstrated that hydrophilic
nd lipophilic statins prevent the progression of IMT,
hich indicates prevention of atherosis (9). However, effects
f statins on sclerosis are still unclear. One study demon-
trated that short-term therapy with pravastatin (hydro-
hilic) in patients with mild-to-moderate HL improved the
ipid profile, but did not induce obvious changes in the
unctional properties of the large arteries (18). We also
howed that pravastatin did not induce a decrease of the IB
alues of carotid media, which would indicate improvement
tween at baseline and after 12 months and pulse-wave velocity (PWV)
ge of the ratio of apolipoprotein B to apolipoprotein A-I between baseline
glycerides.ues be
chanf sclerosis (12). In addition, a randomized trial demon-
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Effects of Fluvastatin on the Carotid Media December 6, 2005:2031–7trated that pravastatin therapy for 12 months did not
ecrease PWV (19). These studies indicated that hydro-
hilic statin may have less effect on arterial sclerosis than
therosis.
It is recognized that the structure of the aortic media is
losely related to the biomechanical tangential or circum-
erential strain resulting from intra-luminal hydrostatic
ressure (20). In addition, the histological structure of the
ortic media influences the degree of arterial sclerosis (21).
e previously reported that the IB values of carotid media
eflected both the fragmentation of elastic fiber and the
ensity of collagen fiber (8). Elastic fiber in arterial media
lays an important role in maintaining the elasticity of the
rteries, whereas collagen fiber functions to maintain the
trength of the arteries. In addition, changes in the ratio of
ollagen to elastin, rather than the deposition of lipids, have
een known to affect the elastic behavior and function
f the arterial wall (22). In the present study, fluvastatin
lipophilic) decreased IB values, indicating reduction of
clerosis. Changes of IB values after lipophilic statin therapy
ay be due to the direct effect of statin on these fibers.
owever, medial sclerosis is induced not only by the
tructural change of these fibers, but also by the degenera-
ion of smooth muscle cells and deposits of calcium, lipids,
nd mucopolysaccharides in the arterial media (23). The
recise mechanisms by which fluvastatin reduces arterial
clerosis have remained unclear. The present study cannot
dentify the direct mechanism by which statins affect arterial
edia, but does suggest the effect they have on arterial
clerosis.
There were interesting findings in the present study. The
hange in IB values after 12 months of statin therapy was
ignificantly correlated with ApoB/A-I, LDL-C, tri-
lycerides, and ApoB. Also, the change in PWV after 12
onths of statin therapy significantly correlated with
ApoB/A-I and triglycerides. With respect to the athero-
is, a previous study reported that the change in IMT after
wo years of statin therapy weakly correlated with percent
DL-C reduction (r  0.14, p  0.01) (24). In addition, a
eta-analysis demonstrated that there was a correlation
etween the average IMT reduction and LDL-C reduction
r  0.65, p  0.004) (25). However, there has been no
eport of the relationship between the degree of lipid
eduction and the degree of vascular stiffness parameters
uch as PWV and IB values. To our knowledge, this is the
rst report that demonstrates these relationships. Further-
ore, the present study suggests the efficacy of ApoB/A-I as
ell as LDL-C as a target for statin treatment as demon-
trated by other recent studies (26,27).
tudy limitations. Because the number of patients in our
nalysis was small, the relationship between statin therapy
nd the reduction of hs-CRP, the correlation between
IMT and ApoB/A-I, and the relevant evidence between
B values and vascular events that could be indicated in a
arge study have not been shown. In addition, analysis of the
ncidence of vascular events was not possible because the
1resent study is not a long-term follow-up study of several
ears. Large-scale follow-up studies, which include an
nalysis of the incidence of vascular events and strokes, will
e required in the future. Future long-term studies address-
ng the relationship between arterial sclerosis and cardiovas-
ular events must determine whether arterial sclerosis is a
isk factor for cardiovascular events, independent of its
ssociation with arterial atherosis.
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